These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 21738027)

  • 21. The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety.
    Golubchik P; Golubchik L; Sever JM; Weizman A
    Int Clin Psychopharmacol; 2014 Sep; 29(5):274-8. PubMed ID: 24743562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report.
    Golubchik P; Sever J; Weizman A; Zalsman G
    Clin Neuropharmacol; 2011; 34(3):108-10. PubMed ID: 21586916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
    Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
    Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
    Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.
    Levin FR; Evans SM; Brooks DJ; Garawi F
    Drug Alcohol Depend; 2007 Feb; 87(1):20-9. PubMed ID: 16930863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of methylphenidate on the power spectrum of ADHD children - an MEG study.
    Wienbruch C; Paul I; Bauer S; Kivelitz H
    BMC Psychiatry; 2005 Jul; 5():29. PubMed ID: 16042816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
    Konstenius M; Jayaram-Lindström N; Beck O; Franck J
    Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review.
    Koneski JA; Casella EB; Agertt F; Ferreira MG
    Epilepsy Behav; 2011 Jul; 21(3):228-32. PubMed ID: 21524941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of methylphenidate in adults with attention deficit disorder with hyperactivity].
    Gauillard J; Castelnau C; Vacheron-Trystram MN; Cheref S; Caroli F
    Encephale; 1997; 23(4):251-6. PubMed ID: 9417389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.
    Robison RJ; Reimherr FW; Gale PD; Marchant BK; Williams ED; Soni P; Halls C; Strong RE
    Ann Clin Psychiatry; 2010 May; 22(2):94-102. PubMed ID: 20445836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P; Hsu HY; Chiou SS; Chao MC
    Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey.
    Lensing MB; Zeiner P; Sandvik L; Opjordsmoen S
    J Clin Psychiatry; 2013 Jan; 74(1):e87-93. PubMed ID: 23419235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
    Yoo HK; Park S; Wang HR; Lee JS; Kim K; Paik KW; Yum MS; Ko TS
    Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attention deficit/hyperactivity disorder in adults.
    Moss SB; Nair R; Vallarino A; Wang S
    Prim Care; 2007 Sep; 34(3):445-73, v. PubMed ID: 17868755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.